A preclinical study reported that CT-179 remodels the tumor microenvironment, turns “cold” tumors “hot,” and enhances the efficacy of immune checkpoint inhibitors.
Fariba has over 30 years of pharmaceutical and R&D experience, including more than 20 years in clinical quality and GCP. Expertise includes global compliance, quality assurance, clinical research operations, and Cardiology, Oncology, CNS, Diabetes, and Immunology.
Martin Simonetti has been CEO of PBS Biotech since 2025, after 12 years advising small and mid-sized biotechnology companies. He previously served as VLST's president and CEO and held senior roles at Dendreon.
Curtana Pharmaceuticals says standard brain cancer care is inadequate because traditional therapies target rapidly dividing tumor cells but leave cancer stem cells that can drive recurrence.
Curtana Pharmaceuticals is advancing a novel, dual-action therapy designed to halt recurrence by eradicating cancer stem cells and reversing tumor-driven immune suppression in adults and pediatric brain cancers.
